Subsequently, we implemented CBX2-knockdown LN229R, and the results demonstrated that CBX2 knockdown not only slowed glioma growth and prolonged survival without TMZ treatment but also significantly enhanced tumor suppression and extended survival when combined with TMZ treatment. Here, CBX2 is linked to neoplasm.